DNLI — Denali Therapeutics Inc.
6 mentions in the last 24 hours · 0.03% of all mentions
Why people talked about DNLI (2026-11-04)
- Denali Therapeutics reported Q3 2026 EPS of $0.37, beating estimates by 186.0%.
- Revenue of $17.8M missed the $20.8M estimate by 14.7%.
- The company issued a press release regarding financial results for the quarter ended September 30, 2026.
| Bluesky | 2 | community |
| GDELT | 2 | news |
| RSS Bundle | 1 | news |
| SEC EDGAR 8-K | 1 | filings |